查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916869

慢性肾臟病药物市场按药物类别、给药途径、最终用户和分销管道划分－2026-2032年全球预测

Chronic Kidney Disease Medication Market by Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，慢性肾臟病药物市场价值将达到 155.4 亿美元，到 2026 年将成长至 162.5 亿美元，到 2032 年将达到 216.5 亿美元，复合年增长率为 4.85%。

关键市场统计数据
基准年 2025 155.4亿美元
预计年份：2026年 162.5亿美元
预测年份 2032 216.5亿美元
复合年增长率 (%) 4.85%

权威见解将慢性肾臟病药物置于临床实务变革、病患诊疗路径和医疗系统优先事项之中。

慢性肾臟病(CKD) 仍然是一个涉及复杂病理学、不断发展的治疗方法以及日益增长的医疗保健系统需求的复杂临床挑战。本导言重点阐述了 CKD 中贫血、矿物质和骨骼疾病以及缺铁的驱动机制，建立了临床背景，并将药物干预措施置于当代标准治疗方案之中。本导言强调了治疗创新、处方集定位和供应链韧性对于肾臟科未来发展的重要性。

科学突破、监管机构对真实世界证据的重视以及医疗服务模式的创新正在重塑慢性肾臟病治疗的范式。

慢性肾臟病治疗格局正处于变革性的转折点，这主要得益于科学进步、监管调整以及支付方期望的转变。促红血球生成素、口服和静脉铁剂、标靶磷酸盐结合粘合剂、维生素D受体活化剂和拟钙剂等领域的最新进展，拓展了治疗选择，并改变了临床医生製定治疗方案的方式。这种变革不仅限于药物研发，也体现了生物标记、诊断技术和病患监测等方面的综合进步，从而能够实现更个人化的治疗方法。

对2025年关税调整将对全球慢性肾臟病药物供应链、定价策略和战略韧性规划造成的压力全面评估

2025年关税的实施以及不断变化的贸易政策，增加了慢性肾臟病药物供应链的复杂性，影响了原材料采购、製造成本结构和跨境配送流程。依赖全球供应链的製造商必须重新评估筹资策略和紧急时应对计画，以维持供应的连续性、应对投入成本波动并保障利润率。因此，许多企业正在加快近岸外包的步伐，实现供应商多元化，并重新评估其对单一供应来源的依赖程度。

基于深度细分的观点，解释了慢性肾臟病药物类别中的治疗丛集、给药方法和临床差异

細項分析揭示了慢性肾臟病 (CKD) 治疗过程中不同的治疗丛集和给药方式，这些类别和方式的驱动因素各不相同，包括不同的临床和商业性因素。促红血球生成素构成一个丛集，包括Darbepoetinα、依泊汀α和甲氧基聚乙二醇依泊汀β。这些药物在给药频率、药物动力学特征和给药环境方面存在差异，这影响了肾臟内科诊疗和透析中心的用药模式。由于药物转换通常反映了便利性、贫血治疗疗效和医保报销途径之间的权衡，因此生产商必须使其通讯和证据生成与这些实际的用药驱动因素一致。

不同地区的法规结构、支付方趋势和交付模式将如何影响慢性肾臟病药物的取得、应用和商业化策略

区域趋势对慢性肾臟病治疗领域的治疗可及性、监管路径和商业化策略有显着影响。在美洲，市场进入很大程度上受到医保谈判、支付方处方集选择流程以及日益重视的基于绩效的合约（将医保报销与可衡量的临床终点挂钩）的影响。该地区的临床环境倾向于引入具有令人信服的真实世界证据支持其能够改善患者预后和提高成本效益的创新治疗方法，而分销网络通常与大规模透析机构和综合医疗系统紧密合作。

评估竞争定位、策略伙伴关係以及定义慢性肾臟病治疗产品组合领先地位的证据优先事项

慢性肾臟病治疗领域的企业竞争格局主要体现在广泛的产品组合上，包括促红血球生成素、铁剂、磷酸盐粘合剂、维生素D受体活化剂和拟钙剂，以及在实证医学和生命週期管理方面的投入。主要企业力求透过製剂创新、给药便利性和安全性提升来脱颖而出，同时也投资于辅助服务，例如病患援助计画和数位化药物管理工具，以增强治疗价值。

为製造商提供切实可行的策略指导，帮助他们将证据收集、供应链韧性和相关人员协作相结合，以确保长期价值。

产业领导者应采取多管齐下的策略，整合临床差异化、业务永续营运和相关人员为中心的商业化。首先，应投资产生可靠的比较研究和真实世界证据，以证明患者疗效、耐受性和整体医疗成本方面均有显着改善。这些证据应旨在消除支付方的顾虑，支持基于价值的合约谈判，并透过有针对性的医学教育和同行评审出版物进行传播，从而加速临床医生对该疗法的采纳。

严谨的多源调查方法，结合临床文献、专家访谈和供应链风险分析，确保了研究结果的实际相关性。

本研究整合了监管文件、同行评审的临床文献、公共卫生机构指南以及与临床专家、支付方代表和相关人员的结构化访谈，以全面了解慢性肾臟病药物的现状。数据收集优先考虑临床安全性和有效性方面的主要信息，并辅以观察性研究和真实世界数据，以反映日常治疗模式。专家咨询提供了关于处方行为、地理偏好和地理可及性动态的定性背景资讯。

总之，我们强调，临床差异化、证据产生和供应链韧性将决定 CKD 治疗领域的主导。

总之，慢性肾臟病治疗领域正步入一个新时代，其特点是临床诊疗的细微差别更加深刻、对实证医学的要求更高，以及对供应链韧性的日益重视。治疗细分——包括促红血球生成素、磷酸盐粘合剂剂、维生素D受体活化剂、铁剂和拟钙剂——为临床差异化和以患者为中心的创新提供了多种机会。成功与否取决于能否获得令人信服的真实世界数据，能否设计出能够减轻患者负担的产品和服务，以及能否运用个人化策略应对区域监管和支付方的复杂问题。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章慢性肾臟病药物市场（依药物类别划分）

  • 肾素-血管收缩素系统调节剂
    • 血管收缩素转化酵素抑制剂
    • 血管收缩素素受体阻断剂
    • 直接肾素抑制剂
    • 血管紧张素受体血管收缩素酶抑制剂
  • 钠-葡萄糖共同输送体抑制剂
    • SGLT2抑制剂
    • 双重SGLT1和SGLT2抑制剂
  • 盐皮质激素受体拮抗剂
    • 类固醇类盐皮质激素受体拮抗剂
    • 非类固醇盐皮质激素受体拮抗剂
  • 红血球生成刺激因子
    • 短效促红血球生成因子
    • 长效促红血球生成因子
    • 持续性促红血球生成因子
  • 铁剂治疗
    • 静脉铁剂治疗
      • 蔗糖铁
      • Ferric carboxymaltose
      • 异麦芽糖铁
    • 口服铁剂治疗
      • 铁製剂
      • 铁盐製剂
      • 多醣体铁复合物
  • 磷酸盐粘合剂
    • 钙基磷酸盐结合粘合剂
    • 基于司维拉姆的磷酸盐结合粘合剂
    • 磷酸镧吸附剂
    • 含铁磷酸盐吸附剂
  • 钾吸附剂
    • 聚苯乙烯磺酸盐
    • 派蒂罗马
    • 环硅酸锆钠
  • 维生素D及其类似物
    • 活性维生素D类似物
    • 维生素D补充剂作为膳食补充剂
  • 钙模拟物
  • 利尿剂
    • 袢利尿剂
    • 噻嗪类和噻嗪样利尿剂
    • 保钾利尿剂
  • 降低尿酸的药物
    • 黄嘌呤氧化酶抑制剂
    • 促尿酸排泄药物
  • 降血脂治疗
    • 他汀类药物
    • ezetimibe及相关药物
    • PCSK9抑制剂
  • 免疫抑制剂
    • 皮质类固醇
    • Calcineurin抑制剂
    • 抗增殖剂
    • 生物免疫抑制剂

第九章慢性肾臟病药物市场（依给药途径划分）

  • 口服
  • 静脉注射
  • 皮下注射
  • 肌肉内注射

第十章慢性肾臟病药物市场（依最终用户划分）

  • 医院
  • 透析中心
  • 肾臟病及专科诊所
  • 居家医疗环境
  • 学术研究机构

第十一章慢性肾臟病药物市场（依分销管道划分）

  • 医院药房
  • 零售药房
  • 网路药房
  • 透析中心药房

第十二章 各地区慢性肾臟病药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章慢性肾臟病药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国慢性肾臟病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国慢性肾臟病药物市场

第十六章：中国慢性肾臟病药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer Aktiengesellschaft
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • Otsuka Pharmaceutical Co., Ltd.
  • Sanofi SA
  • Vifor Pharma AG
Product Code: MRR-AE420CB153C0

The Chronic Kidney Disease Medication Market was valued at USD 15.54 billion in 2025 and is projected to grow to USD 16.25 billion in 2026, with a CAGR of 4.85%, reaching USD 21.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.54 billion
Estimated Year [2026] USD 16.25 billion
Forecast Year [2032] USD 21.65 billion
CAGR (%) 4.85%

An authoritative orientation that frames chronic kidney disease therapeutics within clinical practice shifts, patient pathways, and health system priorities

Chronic kidney disease (CKD) remains a multifaceted clinical challenge that intersects complex pathophysiology, evolving therapeutic modalities, and heightened demands on health systems. The introduction to this body of work establishes the clinical context-highlighting the mechanisms that drive anemia, mineral and bone disorder, and iron deficiency in CKD-and situates pharmacologic interventions within contemporary standards of care. This orientation foregrounds why therapeutic innovation, formulary positioning, and supply chain resilience are central to the future of nephrology practice.

Beyond the biological underpinnings, the narrative examines how patient pathways and care delivery models are shifting. Outpatient management, multidisciplinary care teams, and telehealth-enabled monitoring are altering prescribing patterns and treatment adherence dynamics. Moreover, payers and providers increasingly emphasize value-based metrics and real-world evidence in formulary decisions, which has direct implications for how medications are adopted, reimbursed, and integrated into long-term care plans.

Finally, this introduction outlines the scope of therapeutic categories examined and the analytical lenses applied across subsequent sections. It clarifies the interplay between clinical efficacy, safety profiles, route of administration, and patient-centric considerations such as convenience and tolerability. With that foundation, the report progresses into a nuanced analysis of market drivers, regulatory forces, and competitive developments that are reshaping CKD medication strategy.

How scientific breakthroughs, regulatory emphasis on real-world evidence, and care delivery innovations are collectively reshaping chronic kidney disease treatment paradigms

The therapeutic landscape for chronic kidney disease is experiencing transformative inflection driven by scientific advances, regulatory recalibrations, and evolving payer expectations. Recent innovations in erythropoiesis-stimulating agents, oral and intravenous iron formulations, targeted phosphate binders, vitamin D receptor activators, and calcimimetics have collectively expanded treatment options and changed how clinicians sequence therapies. This transformation is not isolated to drug development; it reflects integrated progress across biomarkers, diagnostics, and patient monitoring that enable more personalized treatment regimens.

Concurrently, regulatory authorities have increased the emphasis on safety surveillance and post-marketing evidence, prompting manufacturers to invest in longitudinal data collection and real-world studies. These efforts are reshaping product lifecycles and influencing strategic decisions around label expansions, combination therapies, and evidence generation plans. The net effect is a more dynamic competitive environment where clinical differentiation and health-economic arguments are essential for sustained adoption.

In parallel, shifts in care delivery-such as the broadened use of outpatient infusion centers, home-based care models, and digital adherence tools-are altering route-of-administration preferences and the value proposition of therapeutics. Patient-centered design, from simplified dosing to reduced side-effect burdens, is a growing determinant of prescribing behavior. Together, these scientific, regulatory, and delivery innovations are creating a landscape in which agility, cross-stakeholder collaboration, and robust evidence synthesis will determine which therapies achieve lasting clinical and commercial traction.

Comprehensive assessment of how 2025 tariff shifts have stressed global supply chains, pricing strategies, and strategic resilience planning for CKD therapeutics

The imposition of tariffs and evolving trade policies in 2025 has introduced additional complexity to the supply chains underpinning chronic kidney disease therapeutics, affecting raw material sourcing, manufacturing cost structures, and cross-border distribution flows. Manufacturers dependent on global supply networks have had to reassess procurement strategies and contingency plans to preserve continuity of supply, manage input cost volatility, and protect margin integrity. As a result, many organizations are accelerating nearshoring initiatives, diversifying supplier bases, and reassessing single-source dependencies.

These trade policy dynamics have also influenced pricing strategies and contractual negotiations with payers and healthcare systems. Firms have engaged in more granular cost-to-serve analyses and have revisited tendering approaches to ensure that tariff-related cost pressures do not impede patient access. In some cases, stakeholders have pursued operational efficiencies-such as lean manufacturing investments or revised packaging and distribution models-to offset tariff-driven increases without compromising clinical availability.

Importantly, the cumulative impact extends beyond direct cost effects to strategic planning horizons. Companies are prioritizing supply chain visibility tools, enhancing inventory buffering policies, and expanding collaborative arrangements with logistics partners to minimize disruption. The heightened focus on resilience and supply predictability has become a permanent consideration in product launch planning, lifecycle management, and cross-border commercial strategies within the CKD medication ecosystem.

Deep segmentation-driven perspective explaining therapeutic clusters, administration modalities, and clinical differentiation across CKD medication categories

Segmentation analysis reveals distinct therapeutic clusters and administration modalities that drive differing clinical and commercial considerations across the CKD treatment continuum. Erythropoiesis-stimulating agents form one cluster and include Darbepoetin Alfa, Epoetin Alfa, and Methoxy Polyethylene Glycol Epoetin Beta; these agents vary in dosing frequency, pharmacokinetic profiles, and administration settings, which in turn influence adoption patterns among nephrology practices and dialysis centers. Transitioning between agents often reflects trade-offs between convenience, efficacy in managing anemia, and payer reimbursement pathways, so manufacturers must align messaging and evidence generation to these practical adoption levers.

Phosphate binder therapies comprise another important grouping, encompassing calcium-based binders, lanthanum carbonate, and sevelamer. Each binder category presents unique tolerability and safety profiles, with implications for long-term adherence and mineral metabolism outcomes. Prescribers balance efficacy in phosphate control against risks such as calcium loading, gastrointestinal tolerability, and drug-drug interactions, prompting a focus on patient selection criteria and comparative outcome evidence to support clinical decision-making.

Vitamin D receptor activators represent a further segment and include calcitriol, doxercalciferol, and paricalcitol. Variations in receptor selectivity, hypercalcemia risk, and effects on parathyroid hormone levels shape therapeutic sequencing and dosing strategies. As clinicians aim to optimize bone-mineral disorder management while minimizing adverse events, head-to-head clinical data and safety monitoring protocols become essential components of therapeutic positioning.

Iron supplementation strategies divide into intravenous and oral modalities, each with distinct clinical workflows and adherence considerations. Intravenous formulations such as ferric carboxymaltose, ferric gluconate, ferumoxytol, and iron sucrose are typically utilized in settings where rapid repletion is needed or where oral therapy has failed; their differential safety profiles, infusion times, and operational demands impact site-of-care dynamics. Oral supplements including carbonyl iron, ferrous fumarate, ferrous gluconate, and ferrous sulfate offer convenience and lower upfront costs but face challenges related to gastrointestinal tolerability and variable absorption, which affects sustained hemoglobin maintenance.

Calcimimetics form a critical, focused category with agents such as cinacalcet and etelcalcetide, which modulate parathyroid hormone activity via different administration routes and pharmacologic mechanisms. The choice between oral and intravenous calcimimetics hinges on patient adherence patterns, dialysis center workflows, and comparative side-effect profiles. Across all segments, differentiation strategies that emphasize real-world tolerability, dosing convenience, and measurable clinical endpoints will be central to shaping prescriber preferences and long-term utilization.

How distinct regulatory frameworks, payer dynamics, and care delivery models in key regions influence CKD medication access, adoption, and commercialization strategies

Regional dynamics exert a pronounced influence on therapeutic access, regulatory pathways, and commercialization strategies across the chronic kidney disease medication landscape. In the Americas, market access is strongly shaped by reimbursement negotiations, payer formulary processes, and a growing emphasis on outcomes-based contracting that links reimbursement to measurable clinical endpoints. Clinical practice in this region favors innovation adoption where compelling real-world evidence supports improved patient outcomes and cost-effectiveness, and distribution networks are often aligned with large dialysis organizations and integrated delivery systems.

Within Europe, the Middle East, and Africa, regulatory divergence and variable healthcare financing models create heterogeneous pathways to adoption. European regulatory frameworks and national health technology assessment bodies demand robust comparative effectiveness and health economics data, which can prolong time-to-reimbursement but also incentivize high-quality evidence generation. In the Middle East and Africa, market entry strategies must account for disparities in infrastructure, local manufacturing capacity, and differential access to specialized care, leading to tailored commercial approaches that prioritize supply reliability and clinician education.

Asia-Pacific presents a complex combination of rapid innovation adoption in certain markets, varied regulatory environments, and differing routes of care delivery. Some countries in this region demonstrate high receptivity to next-generation agents and home-based care innovations, while others prioritize cost-containment and local manufacturing. Across all regions, aligning clinical development plans with region-specific regulatory expectations and payer evidence requirements is essential to ensuring timely and broad patient access to therapeutic advances.

Assessment of competitive positioning, strategic partnerships, and evidence-generation priorities that determine leadership in CKD therapeutic portfolios

Competitive dynamics among companies operating in the chronic kidney disease medication space are defined by portfolios that span erythropoiesis-stimulating agents, iron products, phosphate binders, vitamin D receptor activators, and calcimimetics, as well as by investments in evidence generation and lifecycle management. Leading organizations pursue differentiation through innovations in formulation, dosing convenience, and safety profiles, while also investing in ancillary services such as patient support programs and digital adherence tools that enhance therapeutic value.

Partnerships and licensing arrangements have become central to accelerating access to complementary technologies and to expanding geographic reach. Strategic alliances between biologics developers and contract manufacturing organizations, as well as collaborations with specialty pharmacies and infusion providers, underpin many go-to-market models. In parallel, companies increasingly emphasize real-world evidence collection, observational cohorts, and payer-oriented health economic dossiers as part of launch readiness and post-marketing strategies.

Competitive positioning also reflects how firms navigate regulatory requirements and tariff-driven supply chain challenges, with resilient manufacturers leveraging diversified sourcing, scalable manufacturing footprints, and strong quality systems to mitigate disruption. Ultimately, companies that integrate robust clinical differentiation with pragmatic commercial execution-grounded in stakeholder engagement across clinicians, payers, and patients-are positioned to secure sustained relevance in a rapidly evolving therapeutic environment.

Actionable strategic guidance for manufacturers to combine evidence generation, supply resilience, and stakeholder collaboration to solidify long-term value

Industry leaders should adopt a multifaceted strategy that aligns clinical differentiation with operational resilience and stakeholder-centric commercialization. First, invest in robust comparative and real-world evidence generation that demonstrates meaningful improvements in patient outcomes, tolerability, and total cost of care. Such evidence should be tailored to address payer concerns and to support value-based contracting discussions, and it should be disseminated through targeted medical education and peer-reviewed publications to accelerate clinician adoption.

Second, strengthen supply chain resilience by diversifying supplier relationships, increasing visibility across upstream inputs, and evaluating nearshoring or regional manufacturing options where feasible. These operational moves will reduce exposure to tariff volatility and cross-border disruptions while preserving treatment continuity for vulnerable patient populations. Third, prioritize patient-centric design in product development and service offerings; simplifying dosing schedules, minimizing adverse effect burdens, and integrating adherence support will directly influence long-term utilization and outcomes.

Finally, cultivate cross-sector partnerships with payers, providers, and specialty care networks to co-develop outcome-based agreements and streamlined access pathways. Engage early with regional regulatory and reimbursement stakeholders to align evidence generation with decision criteria, and design launch plans that incorporate flexible pricing models and targeted access programs. By combining scientific rigor, supply resilience, and collaborative commercial models, organizations can navigate short-term disruptions while building enduring clinical and market advantage.

Rigorous, multi-source methodology combining clinical literature, expert consultations, and supply chain risk analysis to ensure actionable validity

This research synthesizes regulatory documents, peer-reviewed clinical literature, publicly available guidance from health authorities, and structured interviews with clinical experts, payer representatives, and industry stakeholders to build a comprehensive understanding of the chronic kidney disease medication landscape. Data collection prioritized primary sources for clinical safety and efficacy, complemented by observational studies and real-world datasets to reflect everyday treatment patterns. Expert consultations provided qualitative context on prescribing behavior, site-of-care preferences, and regional access dynamics.

Analytical methods incorporated comparative efficacy appraisal, safety profile differentiation, and a qualitative assessment of supply chain risk factors influenced by regulatory and trade developments. The approach emphasized triangulation-cross-verifying findings across multiple independent sources to strengthen validity-and documented assumptions and limitations transparently. Special attention was paid to the methodological rigor of included studies, and evidence hierarchies guided how findings influenced strategic conclusions.

Finally, the methodology included a stakeholder validation phase in which preliminary insights were reviewed with practicing nephrologists, formulary decision-makers, and distribution partners to ensure practical relevance and to refine recommendations. This iterative process enhanced the applicability of recommendations and ensured that the final analysis reflects both robust evidence synthesis and grounded real-world perspectives.

Concluding synthesis emphasizing how clinical differentiation, evidence generation, and supply chain resilience will determine leadership in CKD therapeutics

In conclusion, the chronic kidney disease therapeutic environment is entering an era marked by greater clinical nuance, heightened evidence expectations, and an intensified focus on supply chain resilience. Therapeutic segmentation across erythropoiesis-stimulating agents, phosphate binders, vitamin D receptor activators, iron supplements, and calcimimetics presents diverse opportunities for clinical differentiation and patient-centered innovation. Success will hinge on the ability to generate compelling real-world data, to design products and services that reduce patient burden, and to navigate regional regulatory and payer complexities with tailored strategies.

Operational excellence in manufacturing and distribution remains a core enabler of access, especially in light of recent trade policy pressures that have underscored the fragility of single-source supply chains. Firms that proactively invest in diversified sourcing, transparent quality systems, and collaborative partnerships with delivery networks will be better positioned to maintain continuity of care. Ultimately, organizations that integrate scientific innovation with pragmatic commercialization, rigorous evidence generation, and resilient operations will lead the next wave of therapeutic advances for patients with chronic kidney disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Kidney Disease Medication Market, by Drug Class

  • 8.1. Renin Angiotensin System Modulators
    • 8.1.1. Angiotensin Converting Enzyme Inhibitors
    • 8.1.2. Angiotensin Receptor Blockers
    • 8.1.3. Direct Renin Inhibitors
    • 8.1.4. Angiotensin Receptor Neprilysin Inhibitors
  • 8.2. Sodium Glucose Cotransporter Inhibitors
    • 8.2.1. SGLT2 Inhibitors
    • 8.2.2. Dual SGLT1 And SGLT2 Inhibitors
  • 8.3. Mineralocorticoid Receptor Antagonists
    • 8.3.1. Steroidal Mineralocorticoid Receptor Antagonists
    • 8.3.2. Nonsteroidal Mineralocorticoid Receptor Antagonists
  • 8.4. Erythropoiesis Stimulating Agents
    • 8.4.1. Short Acting Erythropoiesis Stimulating Agents
    • 8.4.2. Long Acting Erythropoiesis Stimulating Agents
    • 8.4.3. Continuous Erythropoiesis Receptor Activators
  • 8.5. Iron Therapies
    • 8.5.1. Intravenous Iron Therapies
      • 8.5.1.1. Iron Sucrose
      • 8.5.1.2. Ferric Carboxymaltose
      • 8.5.1.3. Ferric Derisomaltose
    • 8.5.2. Oral Iron Therapies
      • 8.5.2.1. Ferrous Salt Preparations
      • 8.5.2.2. Ferric Salt Preparations
      • 8.5.2.3. Polysaccharide Iron Complexes
  • 8.6. Phosphate Binders
    • 8.6.1. Calcium Based Phosphate Binders
    • 8.6.2. Sevelamer Based Phosphate Binders
    • 8.6.3. Lanthanum Based Phosphate Binders
    • 8.6.4. Iron Based Phosphate Binders
  • 8.7. Potassium Binders
    • 8.7.1. Sodium Polystyrene Sulfonate
    • 8.7.2. Patiromer
    • 8.7.3. Sodium Zirconium Cyclosilicate
  • 8.8. Vitamin D And Analogs
    • 8.8.1. Active Vitamin D Analogs
    • 8.8.2. Nutritional Vitamin D Supplements
  • 8.9. Calcimimetics
  • 8.10. Diuretics
    • 8.10.1. Loop Diuretics
    • 8.10.2. Thiazide And Thiazide Like Diuretics
    • 8.10.3. Potassium Sparing Diuretics
  • 8.11. Uric Acid Lowering Agents
    • 8.11.1. Xanthine Oxidase Inhibitors
    • 8.11.2. Uricosuric Agents
  • 8.12. Lipid Lowering Therapies
    • 8.12.1. Statins
    • 8.12.2. Ezetimibe And Related Agents
    • 8.12.3. PCSK9 Inhibitors
  • 8.13. Immunosuppressive Agents
    • 8.13.1. Corticosteroids
    • 8.13.2. Calcineurin Inhibitors
    • 8.13.3. Antiproliferative Agents
    • 8.13.4. Biologic Immunosuppressants

9. Chronic Kidney Disease Medication Market, by Route Of Administration

  • 9.1. Oral Route
  • 9.2. Intravenous Route
  • 9.3. Subcutaneous Route
  • 9.4. Intramuscular Route

10. Chronic Kidney Disease Medication Market, by End User

  • 10.1. Hospitals
  • 10.2. Dialysis Centers
  • 10.3. Nephrology And Specialty Clinics
  • 10.4. Home Care Settings
  • 10.5. Academic And Research Institutions

11. Chronic Kidney Disease Medication Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Dialysis Center Pharmacies

12. Chronic Kidney Disease Medication Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Chronic Kidney Disease Medication Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Chronic Kidney Disease Medication Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Chronic Kidney Disease Medication Market

16. China Chronic Kidney Disease Medication Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amgen Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Baxter International Inc.
  • 17.8. Bayer Aktiengesellschaft
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Eli Lilly and Company
  • 17.11. Fresenius Medical Care AG & Co. KGaA
  • 17.12. Otsuka Pharmaceutical Co., Ltd.
  • 17.13. Sanofi S.A.
  • 17.14. Vifor Pharma AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RENIN ANGIOTENSIN SYSTEM MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RENIN ANGIOTENSIN SYSTEM MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RENIN ANGIOTENSIN SYSTEM MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RENIN ANGIOTENSIN SYSTEM MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIRECT RENIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIRECT RENIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIRECT RENIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DUAL SGLT1 AND SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DUAL SGLT1 AND SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DUAL SGLT1 AND SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SHORT ACTING ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SHORT ACTING ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SHORT ACTING ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LONG ACTING ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LONG ACTING ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LONG ACTING ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS IRON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS IRON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS IRON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON SUCROSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON SUCROSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON SUCROSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC DERISOMALTOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC DERISOMALTOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC DERISOMALTOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL IRON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL IRON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL IRON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERROUS SALT PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERROUS SALT PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERROUS SALT PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC SALT PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC SALT PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY FERRIC SALT PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POLYSACCHARIDE IRON COMPLEXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POLYSACCHARIDE IRON COMPLEXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POLYSACCHARIDE IRON COMPLEXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PHOSPHATE BINDERS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCIUM BASED PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCIUM BASED PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCIUM BASED PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SEVELAMER BASED PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SEVELAMER BASED PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SEVELAMER BASED PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LANTHANUM BASED PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LANTHANUM BASED PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LANTHANUM BASED PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON BASED PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON BASED PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON BASED PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM BINDERS, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM POLYSTYRENE SULFONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM POLYSTYRENE SULFONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM POLYSTYRENE SULFONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PATIROMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PATIROMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PATIROMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM ZIRCONIUM CYCLOSILICATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM ZIRCONIUM CYCLOSILICATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM ZIRCONIUM CYCLOSILICATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY VITAMIN D AND ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY VITAMIN D AND ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY VITAMIN D AND ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY VITAMIN D AND ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ACTIVE VITAMIN D ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ACTIVE VITAMIN D ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ACTIVE VITAMIN D ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NUTRITIONAL VITAMIN D SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NUTRITIONAL VITAMIN D SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NUTRITIONAL VITAMIN D SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCIMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCIMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCIMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIURETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIURETICS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LOOP DIURETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LOOP DIURETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LOOP DIURETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY THIAZIDE AND THIAZIDE LIKE DIURETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY THIAZIDE AND THIAZIDE LIKE DIURETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY THIAZIDE AND THIAZIDE LIKE DIURETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM SPARING DIURETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM SPARING DIURETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM SPARING DIURETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URIC ACID LOWERING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URIC ACID LOWERING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URIC ACID LOWERING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URIC ACID LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URICOSURIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URICOSURIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LIPID LOWERING THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LIPID LOWERING THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LIPID LOWERING THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LIPID LOWERING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY STATINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY STATINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY STATINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY EZETIMIBE AND RELATED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY EZETIMIBE AND RELATED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY EZETIMIBE AND RELATED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PCSK9 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PCSK9 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY BIOLOGIC IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY BIOLOGIC IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY BIOLOGIC IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL ROUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL ROUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL ROUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS ROUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS ROUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS ROUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SUBCUTANEOUS ROUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SUBCUTANEOUS ROUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SUBCUTANEOUS ROUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAMUSCULAR ROUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAMUSCULAR ROUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAMUSCULAR ROUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NEPHROLOGY AND SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NEPHROLOGY AND SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY NEPHROLOGY AND SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIALYSIS CENTER PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIALYSIS CENTER PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIALYSIS CENTER PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RENIN ANGIOTENSIN SYSTEM MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PHOSPHATE BINDERS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM BINDERS, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY VITAMIN D AND ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIURETICS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URIC ACID LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LIPID LOWERING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY RENIN ANGIOTENSIN SYSTEM MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY INTRAVENOUS IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ORAL IRON THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY PHOSPHATE BINDERS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY POTASSIUM BINDERS, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY VITAMIN D AND ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DIURETICS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY URIC ACID LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY LIPID LOWERING THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA CHRONIC KIDNEY DISEASE MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CHRONIC